120 related articles for article (PubMed ID: 10420140)
1. Postural skin colour changes during the corticosteroid blanching assay.
Henry F; Fumal I; Piérard GE
Skin Pharmacol Appl Skin Physiol; 1999; 12(4):199-210. PubMed ID: 10420140
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the bioactivity of mometasone furoate 0.1% fatty cream, betamethasone dipropionate 0.05% cream and betamethasone valerate 0.1% cream in humans. Inhibition of UV-B-induced inflammation monitored by laser Doppler blood flowmetry.
Bjerring P
Skin Pharmacol; 1993; 6(3):187-92. PubMed ID: 8274288
[TBL] [Abstract][Full Text] [Related]
3. Comparison of skin atrophy and vasoconstriction due to mometasone furoate, methylprednisolone and hydrocortisone.
Hoffmann K; Auer T; Stücker M; Hoffmann A; Altmeyer P
J Eur Acad Dermatol Venereol; 1998 Mar; 10(2):137-42. PubMed ID: 9553910
[TBL] [Abstract][Full Text] [Related]
4. Quantification of skin-colour changes induced by topical corticosteroid preparations using the Minolta Chroma Meter.
Queille-Roussel C; Poncet M; Schaefer H
Br J Dermatol; 1991 Mar; 124(3):264-70. PubMed ID: 2018732
[TBL] [Abstract][Full Text] [Related]
5. Onset of the vasoconstrictor effect of diflucortolone valerate, betamethasone valerate, and fluocinolone acetonide ointments applied for varying periods under occlusive dressings.
Szadurski J; Renz F; Gasser D
Dermatologica; 1976; 153(4):236-42. PubMed ID: 1017533
[TBL] [Abstract][Full Text] [Related]
6. Once-daily 0.1% mometasone furoate cream versus twice-daily 0.1% betamethasone valerate cream in the treatment of a variety of dermatoses.
Viglioglia P; Jones ML; Peets EA
J Int Med Res; 1990; 18(6):460-7. PubMed ID: 2292327
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity of different areas of the flexor aspect of the human forearm to corticosteroid-induced skin blanching.
Meyer E; Smith EW; Haigh JM
Br J Dermatol; 1992 Oct; 127(4):379-81. PubMed ID: 1419758
[TBL] [Abstract][Full Text] [Related]
8. Potency assessment of topical corticoids in the vasoconstrictor assay and on tuberculin-induced inflammation.
Schalla W; Schorning S
Skin Pharmacol; 1991; 4(3):191-204. PubMed ID: 1768431
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of activity of different topical corticosteroid creams and ointments using a vasoconstriction assay: superiority of hydrocortisone butyrate over hydrocortisone].
Korting HC; Maslen K; Gross G; Willers C
J Dtsch Dermatol Ges; 2005 May; 3(5):348-53. PubMed ID: 16372801
[TBL] [Abstract][Full Text] [Related]
10. Topical mometasone furoate and betamethasone-17-valerate decrease collagen synthesis to a similar extent in human skin in vivo.
Koivukangas V; Karvonen J; Risteli J; Oikarinen A
Br J Dermatol; 1995 Jan; 132(1):66-8. PubMed ID: 7756153
[TBL] [Abstract][Full Text] [Related]
11. Bioavailability, antipsoriatic efficacy and tolerability of a new light cream with mometasone furoate 0.1%.
Korting HC; Schöllmann C; Willers C; Wigger-Alberti W
Skin Pharmacol Physiol; 2012; 25(3):133-41. PubMed ID: 22353786
[TBL] [Abstract][Full Text] [Related]
12. Different skin thinning potential of equipotent medium-strength glucocorticoids.
Korting HC; Unholzer A; Schäfer-Korting M; Tausch I; Gassmueller J; Nietsch KH
Skin Pharmacol Appl Skin Physiol; 2002; 15(2):85-91. PubMed ID: 11867964
[TBL] [Abstract][Full Text] [Related]
13. Bioequivalence of 0.1% mometasone furoate lotion to 0.1% mometasone furoate hydrogel.
Greive KA; Barnes TM
Australas J Dermatol; 2016 May; 57(2):e39-45. PubMed ID: 25545549
[TBL] [Abstract][Full Text] [Related]
14. Topical therapy with fluorinated and non-fluorinated corticosteroids in patients with atopic dermatitis.
Gregurek-Novak T
J Eur Acad Dermatol Venereol; 2001 Jan; 15(1):81-2. PubMed ID: 11451336
[No Abstract] [Full Text] [Related]
15. Potency ranking of two new topical corticosteroid creams containing 0.1% desonide or 0.05% halometasone utilising the human skin blanching assay.
Meyer E; Smith EW; Haigh JM; Kanfer I
Arzneimittelforschung; 1988 Dec; 38(12):1840-3. PubMed ID: 3245859
[TBL] [Abstract][Full Text] [Related]
16. Parallel intraindividual evaluation of the vasoconstrictory action and the anti-allergic activity of topical corticosteroids.
Seidenari S; Di Nardo A; Mantovani L; Giannetti A
Exp Dermatol; 1997 Apr; 6(2):75-80. PubMed ID: 9209888
[TBL] [Abstract][Full Text] [Related]
17. Comparative potency of formulations of mometasone furoate in terms of inhibition of 'PIRHR' in the forearm skin of normal human subjects measured with laser doppler velocimetry.
Kulhalli P; Chevli T; Karnik R; Sheth M; Mulgaonkar N
Indian J Dermatol Venereol Leprol; 2005; 71(3):170-4. PubMed ID: 16394405
[TBL] [Abstract][Full Text] [Related]
18. In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new.
Kerscher MJ; Hart H; Korting HC; Stalleicken D
Int J Clin Pharmacol Ther; 1995 Apr; 33(4):187-9. PubMed ID: 7620686
[TBL] [Abstract][Full Text] [Related]
19. Possible dosage regimens for topical steroids, assessed by vasoconstrictor assays using multiple applications.
Woodford R; Haigh JM; Barry BW
Dermatologica; 1983; 166(3):136-40. PubMed ID: 6852325
[TBL] [Abstract][Full Text] [Related]
20. Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids.
Spada F; Barnes TM; Greive KA
Australas J Dermatol; 2018 Aug; 59(3):e168-e174. PubMed ID: 29411351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
